Nipro Corporation competitors and similar companiesClear all

Nipro Corporation's competitors and similar companies include Eisai, Kuraray, Takeda Pharmaceutical, Astellas Pharma and Nikkiso.

	Nipro Corporation Nipro Corporation (ニプロ株式会社) is a company that develops medical devices, pharmaceuticals, and pharma packaging.	Eisai Eisai is a research-based human health care company that discovers, develops, packages, and markets pharmaceutical products.	Kuraray Kuraray is a company that manufactures chemicals, synthetic and chemical fibers, and other materials.	Takeda Pharmaceutical Takeda Pharmaceutical is a biopharmaceutical company.	Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.	Nikkiso Nikkiso (日機装株式会社) is a company that engages in industrial, precision equipment, aerospace, and medical businesses.
Founding Date	Founding Date 1954	Founding Date 1941	Founding Date 1926	Founding Date 1781	Founding Date 1923	Founding Date 1953
Type	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Manufacturing & Industrial biotech medical devices packaging pharma	Tags Healthcare drug development hospitals oncology pharma	Tags Manufacturing & Industrial chemicals dental manufacturing equipment pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare diabetes drug development oncology pharma	Tags Manufacturing & Industrial aerospace hvac machinery manufacturing equipment medical devices
Locations	Locations Osaka, JP HQ Bunkyo City, JP Kusatsu, JP Kusatsu, JP Ohdate, JP	Locations Bunkyo City, JP HQ Melbourne, AU Wien, AT Leuven, BE Mississauga, CA see more	Locations Chiyoda City, JP HQ São Paulo, BR Shanghai, CN Suzhou Shi, CN see more	Locations Tokyo, JP HQ The Rocks, AU Linz, AT Wien, AT Lessines, BE Zaventem, BE Sarajevo, BA see more	Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more	Locations Tokyo, JP HQ Shanghai, CN Shanghai, CN Shanghai, CN Shanghai, CN Weihai, CN Hamburg, DE see more
Employees	Employees 36,259	Employees 11,322	Employees 11,3301% increase	Employees 47,3471% increase	Employees 15,4553% decrease	Employees 8,7621% increase
Valuation ($)	Valuation ($) 1.3 b	Valuation ($) 17.6 b	Valuation ($) 3 b	Valuation ($) 51.9 b	Valuation ($) 26.6 b	Valuation ($) 464.8 m
Twitter followers	Twitter followers N/A	Twitter followers 6 k	Twitter followers 908	Twitter followers N/A	Twitter followers 50.4 k	Twitter followers 30
Number of tweets (last 30 days)	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) 36	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) 25	Number of tweets (last 30 days) N/A
Average likes per tweet (last 30 days)	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) 5.5	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) 5.8	Average likes per tweet (last 30 days) N/A
Percentage of tweets with engagement (last 30 days)	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) 97.22%	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) 96%	Percentage of tweets with engagement (last 30 days) N/A
Employee Rating	Employee Rating 3.5	Employee Rating 4.2	Employee Rating N/A	Employee Rating 4	Employee Rating 4.2	Employee Rating N/A
Financial
Revenue (est.)	Revenue (est.) ¥442.5b (FY, 2020)	Revenue (est.) ¥756.2b (FY, 2021)	Revenue (est.) ¥756.4b (FY, 2022)	Revenue (est.) ¥3.6t (FY, 2022)	Revenue (est.) ¥1.3t (FY, 2022)	Revenue (est.) ¥177.1b (FY, 2022)
Cost of goods	Cost of goods ¥308.3b (FY, 2020)	Cost of goods (¥136.4b) (FY, 2021)	Cost of goods ¥449.3b (FY, 2022)	Cost of goods ¥523.7b (FY, 2022)	Cost of goods ¥173.3b (FY, 2022)	Cost of goods ¥121.6b (FY, 2022)
Gross profit	Gross profit ¥134.2b (FY, 2020)	Gross profit ¥634.4b (FY, 2021)	Gross profit ¥307.1b (FY, 2022)	Gross profit ¥3.1t (FY, 2022)	Gross profit ¥1.2t (FY, 2022)	Gross profit ¥93.7b (FY, 2022)
Net income	Net income (¥11.6b) (FY, 2020)	Net income ¥45.7b (FY, 2021)	Net income ¥55.6b (FY, 2022)	Net income ¥230.2b (FY, 2022)	Net income ¥124.1b (FY, 2022)	Net income ¥13.8b (FY, 2022)
Operating ⚠
Filed Trials Products (Oncology)	Filed Trials Products (Oncology) N/A	Filed Trials Products (Oncology) 2 (Jul, 2018)	Filed Trials Products (Oncology) N/A	Filed Trials Products (Oncology) 5 (May, 2021)	Filed Trials Products (Oncology) N/A	Filed Trials Products (Oncology) N/A
Phase I Trials Products (Oncology)	Phase I Trials Products (Oncology) N/A	Phase I Trials Products (Oncology) 11 (Jul, 2019)	Phase I Trials Products (Oncology) N/A	Phase I Trials Products (Oncology) 1 (Jul, 2019)	Phase I Trials Products (Oncology) 1 (FY, 2020)	Phase I Trials Products (Oncology) N/A
Phase I/II Trials Products (Oncology)	Phase I/II Trials Products (Oncology) N/A	Phase I/II Trials Products (Oncology) 6 (Jul, 2019)	Phase I/II Trials Products (Oncology) N/A	Phase I/II Trials Products (Oncology) 12 (May, 2021)	Phase I/II Trials Products (Oncology) N/A	Phase I/II Trials Products (Oncology) N/A
Phase II Trials Products (Oncology)	Phase II Trials Products (Oncology) N/A	Phase II Trials Products (Oncology) 9 (Jul, 2019)	Phase II Trials Products (Oncology) N/A	Phase II Trials Products (Oncology) 8 (Oct, 2019)	Phase II Trials Products (Oncology) 1 (FY, 2020)	Phase II Trials Products (Oncology) N/A
Phase III Trials Products (Oncology)	Phase III Trials Products (Oncology) N/A	Phase III Trials Products (Oncology) 10 (Jul, 2019)	Phase III Trials Products (Oncology) N/A	Phase III Trials Products (Oncology) 8 (May, 2021)	Phase III Trials Products (Oncology) 4 (Oct, 2020)	Phase III Trials Products (Oncology) N/A